Highlights and Quick Summary
- Net Aquisitions for the quarter ending September 29, 2020 was $-880 Million (a -97.7% decrease compared to previous quarter)
- Year-over-year quarterly Net Aquisitions increased by 33.54%
- Annual Net Aquisitions for 2019 was $-1.14 Billion (a 54.21% increase from previous year)
- Annual Net Aquisitions for 2018 was $-736 Million (a 138.96% increase from previous year)
- Annual Net Aquisitions for 2017 was $-308 Million (a -88.83% decrease from previous year)
- Twelve month Net Aquisitions ending September 29, 2020 was $-39.9 Billion (a 2.16% increase compared to previous quarter)
- Twelve month trailing Net Aquisitions increased by 3412.69% year-over-year
Trailing Net Aquisitions for the last four month:
|29 Sep '20||29 Jun '20||30 Mar '20||30 Dec '19|
|$-39.9 Billion||$-39 Billion||$-827 Million||$-1.14 Billion|
Visit stockrow.com/ABBV for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.
Historical Net Aquisitions of AbbVie Inc.Most recent Net Aquisitionsof ABBV including historical data for past 10 years.
Interactive Chart of Net Aquisitions of AbbVie Inc.
AbbVie Inc. Net Aquisitions for the past 10 Years (both Annual and Quarterly)
(All values are in $ million)
Business Profile of AbbVie Inc.
Industry: Drug Manufacturers—General
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the United States, Japan, Germany, Canada, France, Spain, Italy, the Netherlands, the United Kingdom, Brazil, and internationally. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal BehÃ§et's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenstrÃ¶m's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C virus (HCV); TECHNIVIE to treat adults with genotype 4 HCV infection; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides SYNAGIS that protects at-risk infants from severe respiratory disease; KALETRA, a prescription anti-HIV-1 medicine; CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; and Lupron, a product for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; and Sevoflurane, an anesthesia product. It has collaborations with Calico Life Sciences LLC; Alector, Inc.; Janssen Biotech, Inc.; Frontier Medicines, Corp.; Jacobio Pharmaceuticals; I-Mab; and Genmab A/S. The company was incorporated in 2012 and is based in North Chicago, Illinois.